1.1Intestinal enzyme inhibition
The tablet releases an alpha-glucosidase inhibitor taken with a carbohydrate-containing meal. The inhibitor slows the breakdown of starch-derived carbohydrates into glucose at the small-intestinal brush border.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The tablet releases an alpha-glucosidase inhibitor taken with a carbohydrate-containing meal. The inhibitor slows the breakdown of starch-derived carbohydrates into glucose at the small-intestinal brush border.
A powder containing psyllium husk is dispersed in water and consumed with a meal. The hydrated fiber increases the viscosity of intestinal contents and slows glucose absorption.
A tablet releases a biguanide that enters the circulation after intestinal absorption. The compound reduces hepatic glucose output, which lowers fasting blood glucose.
A tablet releases an inhibitor of the sodium-glucose cotransporter in the proximal renal tubule. Inhibition reduces the fraction of filtered glucose returned to the bloodstream and increases urinary glucose excretion.
A tablet delivers an inhibitor of dipeptidyl peptidase 4, an enzyme that degrades endogenous incretin hormones. The longer-lived incretin signal increases glucose-dependent insulin secretion and reduces glucagon secretion when blood glucose is elevated.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary inpatient unit stores individually packaged oral doses of the live bacterial strain. The caregiver empties one package into a small serving of the animal’s prescribed wet food and offers it in a separate bowl before the main meal. The caregiver records the package identifier, administration time, and whether the animal consumes the entire serving.
A soft chew replaces the capsule shell and loose powder of an encapsulated oral formulation. A premeasured portion of dried live culture is enclosed in a soft feed matrix after the matrix cools to room temperature. Each chew is sealed individually, and representative units undergo viable plate counts after assembly and at the end of the intended storage period.
A study schedule divides a daily total of 1 × 10⁹ viable bacteria into two oral portions of 5 × 10⁸ viable bacteria each. Separate sachets hold the morning and evening portions, which are offered 12 hours apart. A comparison group receives the same daily total in one portion, and both groups follow the same feeding and glucose sampling schedules.
A glucose monitor with a subcutaneous sensor records interstitial glucose during a veterinary feeding study. A caregiver records each oral dose and meal time in an electronic log that uses the same clock as the monitor. Analysis software aligns the sensor readings with meal times and calculates the glucose excursion above the premeal reading over the next two hours.
A powder filling station connects a gravimetric feeder and a checkweigher to a controller that reads a lot-specific viable count in colony-forming units per gram. The controller divides the target colony-forming units per sachet by the measured count per gram to calculate the powder fill mass. The checkweigher diverts sachets outside the programmed mass tolerance, and finished samples undergo a separate viable count to verify the delivered amount.
A hard cellulose capsule contains freeze-dried cells of the specified strain blended with a dry carrier. The capsule shell dissolves after swallowing and releases the powder into gastrointestinal fluid.
A dry powder containing the specified strain adheres to cooled feed pellets through a thin edible oil coating. The animal consumes the coated pellets, and the cells disperse as the pellets hydrate in the digestive tract.
One premeasured portion provides 100 million viable bacteria per day. A lot-specific viable count per gram determines the powder mass placed in each portion.
Two oral portions each provide 50 million viable bacteria and are administered about 12 hours apart. Together the portions deliver 100 million viable bacteria per 24-hour period.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Besides the oral dosage form, the pharmaceutical composition containing the isolated Pediococcus acidilactici 05B0111 can also be formulated into a suitable dosage form for topical administration (e.g., percutaneous administration or intranasal administration).A · US 2011/0091432 A1 · ¶ 38
In another exemplary embodiment, Pediococcus acidilactici P1J e3 alone is administered to animals such as lactating sows and/or to piglets.B · US 9,402,871 B2 · ¶ 32
The eight probiotic treatments were formulated to deliver 1×109 total cfu/pig/day to sows or pigs regardless of whether the total cfu was derived from one organism or a combination of the three selected organisms, with equal amounts (based on CFUs) of each organism included where multiple organisms were used.B · US 9,402,871 B2 · ¶ 75
An empty cell means only that no passage was reproduced there.
However, EPS produced by bacteria are usually unstable, and yield of the same is normally very low.A · US 2011/0091432 A1 · ¶ 9
Since EPS is in great demand, various factors affecting productivity of EPS of LAB have been investigated so as to develop a new cultivation technology for increasing yield of EPS.A · US 2011/0091432 A1 · ¶ 9
This has led to great interest in the use of direct-fed microbial (DFM) additives to aid the weaning transition by preventing the disruption of the gastrointestinal ecosystem that paves the way for pathogen invasion, thereby promoting growth and maintaining health in the young pig.B · US 9,402,871 B2 · ¶ 7
Therefore, bacteria used for DFM products for livestock species are not usually selected to provide bacterial organisms that would be ideally suited for the challenges present in livestock production systems.B · US 9,402,871 B2 · ¶ 8
patent.fyi, US 2026/0355263 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355263/, SHA-256 448f6a1f963a09caefed89c59717f90b305e331a90e9b161db1bd0d69b72666f